New Delay For Teva's Generic Lovenox Bodes Well For Sandoz/Momenta Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
A "minor deficiency letter" from FDA's Office of Generic Drugs seeks responses to questions about Teva's enoxaparin ANDA, the company says.